References
- CDC. National Diabetes Statistic Report. Centers for Disease Control, 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf [Last accessed 21 July 2014]
- Derosa G, Carbone A, D’Angelo A, et al. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Intern Med (Tokyo, Japan) 2013;52:2179-87
- Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States. Diabetes Care 2007;30:1281-2
- Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-80
- CDC. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014
- Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care 2014;37:1367-74
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
- ADA. Standards of medical care in diabetes – 2014. Diabetes Care 2014;37(Suppl 1):S14-S80
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement – executive summary. Endocr Pract 2013;19:536-57
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438-47
- Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-95
- Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87
- Gregoire JP, Sirois C, Blanc G, et al. Persistence patterns with oral antidiabetes drug treatment in newly treated patients – a population-based study. Value Health 2010;13:820-8
- Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Therapeut 2001;23:1311-20
- Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001;24:1411-15
- Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metabol 2013;15:55-61
- Valensi P, Pouvourville G, Benard N, et al. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes the Odyssee Observational Study. American Diabetes Association Annual Conference, San Francisco, 2014
- Danielson E. Health Research Data for the Real World: The MarketScan Databases. Truven Health Analytics, 2014
- Kentucky U. Sulfonylurea Dosage Conversion Table. 2006. Available at: http://www.hosp.uky.edu/pharmacy/formulary/formtools/sulfonylurea.htm [Last accessed 16 May 2013]
- Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002;30:71-9
- Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003;26:1847-51
- Monami M, Dicembrini I, Kundisova L, et al. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metabol 2014:16:833-40
- Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009;10:1781-7
- Ragia G, Tavridou A, Elens L, et al. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. Exp Clinical Endocrinol Diabetes 2014;122:60-3